mm-151
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2012 (NCT01520389)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- mm-151
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02785068 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2016 | Merrimack Pharmaceuticals |
| NCT02538627 | Phase 1 | Aug 1, 2015 | Merrimack Pharmaceuticals |
| NCT01520389 | Phase 1 | Jan 1, 2012 | Merrimack Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merrimack Pharmaceuticals | For profit | 3 | 3 | 2 | 2012 |
1 organizations
Page 1 / 1